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Abstract  
This work explores the use of UV imaging in solid dispersion systems. Solid dispersions are 
one of the common strategies used in improving the dissolution of poorly soluble drugs. 
Three manufacturing techniques (spray drying (SD), freeze drying (FD) and homogenising 
(HG)) are investigated. Differential Scanning Calorimetry (DSC) and X-Ray Powder 
Diffraction (XRPD) was used in characterising the solid dispersions. Advanced imaging was 
implemented to give an insight into how these solid dispersions performed.  The DSC and 
XRPD results showed that all three methods and the various ratios studied produced 
amorphous solid dispersions. Ultra-Violet (UV) imaging of the pseudo Intrinsic 
Dissolution Rate (IDR) deduced only two samples to have superior pseudo IDR values to the 
IDR of the parent drug indomethacin (INDO). The whole dose imaging of the capsule 
formulation however showed all the samples (SD, FD and HG) to have superior dissolution 
to that of INDO which was in contrast to the IDR results. The UV images obtained from the 
determination of the pseudo IDR also showed a phenomenon the authors are reporting for 
the first time where increased polymer (Soluplus) content produced “web-like” strands that 
migrated to the top of the quartz cell which may have been responsible for the low pseudo 
IDR values. The authors also report for the first time using this UV imaging technique, the tip 
of a capsule coming off for drug to go into solution. The area under the curve suggested the 
best five samples dissolution wise to be 1:3 SD > 1:1 HG > 1:1 SD > 1:3 FD > 1:3 HG 
meaning a ratio of INDO to SOL in these dispersion of up to 1:3 being sufficient to produce 
significant dissolution increases. The developed interfacial (surface) area ratio (Sdr) 
highlighted how the surface area of the IDR compacts varied between the batches, in 
particular highlighting larger surface area gains for the FD and HG compacts. A choice of 
instrumentation/techniques to use in making solid dispersions may well come down to cost or 
instrument availability for a formulator as all three techniques were successful in improving 
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the dissolution of indomethacin. This work thus highlights the importance of having both 
complimentary IDR and whole dosage imaging techniques in giving a better understanding of 
solid dispersion systems.  
Keywords: Indomethacin; Soluplus; Amorphous solid dispersions; UV imaging; Surface 
dissolution imaging; Focus variation  
Abbreviations: NCE, new chemical entities; API, active pharmaceutical ingredients; BCS, 
biopharmaceutical classification system; INDO, indomethacin; SOL, soluplus;  PEG, 
polyethene glycol; PVP, polyvinylpyrrolidone; HPMC, hydroxypropyl methylcellulose; SDI, 
surface dissolution imaging; IDR, Intrinsic dissolution rate; DSC, differential scanning 
calorimetry; XRPD, X-ray powder diffraction; SEM, scanning electron microscopy; SD, 
spray dried; FD, freeze dried; HG, homogenised. 
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Introduction 
It is currently estimated that over 80 % of new chemical entities (NCE) have poor aqueous 
solubility [1].  The challenge faced by the pharmaceutical industry is thus improving the 
solubility of poorly water-soluble drugs to enhance their performance in-vivo, and ultimately 
to maximise bioavailability. The Biopharmaceutical classification system (BCS) classifies 
most of these active pharmaceutical ingredients (API) as belonging to class II [2,3]. BCS 
Class II drugs have low solubility and high membrane permeability, and ultimately 
dissolution is the rate-limiting step for the drug to be released from its dosage formulation 
[4]. The improvement of solubility in poorly soluble drugs can be challenging, costly and 
time-consuming. As such, choosing the correct technique is essential and to date, there are 
several methods including salt formation, liquisolid techniques, complexation, cocrystals, 
particle size reduction, solid dispersion and the use of additives in the crystallisation process 
in overcoming this challenge [5–24]. Solid dispersion is a widely used method and has 
resulted in successful improvements of solubility and bioavailability of poorly soluble APIs. 
The challenge often is the selection of an appropriate carrier [25] with most often opting for 
synthetic or naturally water-soluble polymers such as polyethene glycol (PEG), soluplus, 
polyvinylpyrrolidone (PVP) or hydroxypropyl methylcellulose (HPMC) for a successful 
formulation in which the API is often molecularly dispersed within the carrier [21,26–30].  
Intrinsic dissolution rate (IDR) is an important parameter that can help to predict API 
behaviour in vivo and is determined in the early stages in drug development. Intrinsic 
dissolution rates above 0.1 mg min−1 cm−2 of APIs are generally considered highly soluble 
whereas rates below this limit often indicate the API has low solubility [31]. One of the aims 
in this research paper is to explore the effect of three preparation methods on IDR values of a 
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model drug indomethacin (INDO) and its pseudo IDR for its solid dispersions with 
Soluplus. The Surface Dissolution Imaging (SDI) instrument (Pion Inc, USA), has been used 
for various applications as well as determining IDRs for APIs due to its compound sparing 
approach [16,32–41]. SDI has also been used to evaluate solid dispersions of nilotinib 
with hydroxypropyl methylcellulose phthalate [42]. This instrument typically requires 5–
10 mg of an API with an experimental run time of about 20–30 min in IDR determinations. 
The SDI also supports a wide range of wavelengths allowing a diverse range of analysis 
albeit only one wavelength can be used at a time. The version 2 of the of the SDI 
instrument (SDI2), now has the ability to record UV data at 2 wavelengths simultaneously 
with a range of wavelengths (255, 280, 300 and 320 nm) in determining IDR values. This 
work also uses a focus variation instrument (Alicona Imaging GmbH, Graz, Austria) to 
provide information with regards to the surface metrology of the compacts prepared pre IDR 
or pseudo IDR measurements to give insights as to the influence of the manufacturing 
process on the topography of compacts. This technology used in micro-precision 
manufacturing is typically used for quality assurance [43–45] and acquires topographic 
surface height data in profile (2D) and areal (3D) formats along with true colour surface 
images. The SDI2 also has an additional wavelength of 520 nm that allows the imaging of 
events at a visible wavelength to be recorded [46]. The authors have also aimed at exploiting 
the dual wavelength capability of this instrument as well as its ability to image a whole 
dosage form (capsule in this case) in providing insights on the drug release and capsule 
dissolution process which we believe we are reporting for the first time. These advanced 
imaging techniques are of great importance to a formulator due to the added knowledge it 
provides in better understanding these formulations 
2. Materials and Methods 
2.1. Materials 
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Indomethacin was purchased from TCI Chemicals, UK. Soluplus was a kind gift from BASF, 
Germany.  The solvents methanol and ethanol used in the preparation of the solid dispersions 
were of analytical grade and were purchased from Fisher (UK). Phosphate buffer (pH 7.2) 
was the media used for IDR or pseudo IDR determination, solubility testing as well as whole 
dosage imaging and was prepared according to the USP 2003 using sodium hydroxide and 
potassium phosphate monobasic purchased from Fisher (UK) and Acros Organics (Germany) 
respectively.  
2.2. Methods for solid dispersion preparations 
2.2.1. Preparation of spray dried IND:SOL solid dispersions 
Appropriate amounts of IND (8 g at all ratios used) and SOL making the ratios 1:1, 1:3 and 
1:5 by weight were made by dissolving IND and SOL in ethanol (1.6 L) under stirring 
condition (200 rpm). The resultant solutions made were then spray dried using the Labplant 
Spray Drier under the following conditions: pump setting 15 (equivalent to 695 mL/hour), fan 
setting at 25 (equivalent to 3.25 m/s) and an inlet temperature of 90 °C. The collected spray 
dried particles from the three ratios studied were stored in a desiccator at room temperature 
until required.  
2.2.2. Preparation of freeze dried IND:SOL solid dispersions 
1 g IND was weighted and dissolved in 100 mL of methanol under stirring conditions on a 
hot plate (200 rpm at 70 °C to aid IND dissolution). In another beaker, 1 g SOL was also 
dissolved under stirring conditions at room temperature in 100 mL deionised water. The 
beaker containing IND was gradually introduced to the beaker containing SOL under stirring 
(500 rpm at 70 °C to aid solvent evaporation prior to freeze drying). The resultant sample was 
then immersed in liquid nitrogen to freeze prior to freeze drying using the Christ Alpha 2-4 
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LD Plus freeze drier. This sample was collected after it had been freeze dried and labelled 
1:1, stored until required. The same process was employed with regards to making the 1:3 
and 1:5 IND:SOL solid dispersions with the only difference being 3 g or 5 g being used for 
SOL respectively to account for its ratio.  
2.2.3. Preparation of homogenised IND:SOL solid dispersions 
A similar methodology as reported in section 2.2.2 was adopted and modified. Three beakers 
containing 1 g, 3 g or 5 g SOL in 100 mL deionised water under stirring conditions were 
prepared. Another beaker containing a concentrated amount of dissolved INDO in methanol 
equal to 1 g IND in a 20 mL syringe was prepared. Firstly, the beaker containing the 1 g SOL 
in 100 mL was placed under a high pressure homogeniser. A syringe containing 20 mL of the 
concentrated IND (equivalent to 1 g INDO) was added dropwise to the beaker containing 1 g 
SOL (1000 rpm for 10 min). The obtained suspension was then immersed in liquid nitrogen 
to freeze prior to freeze drying using the Christ Alpha 2-4 LD Plus freeze drier. This same 
process was repeated to give the 1:3 and 1:5 ratios. The collected homogenised and freeze 
dried particles from the three ratios were then stored in a desiccator until required. This 
method was used to determine if homogenising had an effect on the freeze-dried samples. 
2.3. Solid state characterisation 
2.3.1. Scanning electron microscopy (SEM) 
Prior to observation on a scanning electron microscope (Jeol JSM-6060CV SEM), each 
sample (INDO, SOL, SD1:1 (1:1 ratio-spray dried sample), SD1:3 (1:3 ratio-spray dried 
sample), SD1:5 (1:5 ratio-spray dried sample), FD1:1 (1:1 ratio-freeze dried sample), FD1:3 
(1:3 ratio-freeze dried sample), FD1:5 (1:5 ratio-freeze dried sample),  HG1:1 (1:1 ratio-
homogenised dried sample), HG1:3 (1:3 ratio- homogenised dried sample) and HG1:5 (1:5 
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ratio-homogenised dried sample)), was mounted on a double-sided adhesive tape on a metal 
stub and sputter-coated with a thin coating of gold/palladium (80:20) for 60 s (Quorum 
SC7620 Sputter Coater) under vacuum. The SEM instrument operating at 10 kV was used to 
obtain the electron micrographs. Different magnifications were taken to aid the study of the 
morphology of the solid dispersions.  
2.3.2. Differential scanning calorimetry (DSC) 
About 5-10 mg of each sample (INDO, SOL, SD1:1 (1:1 ratio-spray dried sample), SD1:3 
(1:3 ratio-spray dried sample), SD1:5 (1:5 ratio-spray dried sample), FD1:1 (1:1 ratio-freeze 
dried sample), FD1:3 (1:3 ratio-freeze dried sample), FD1:5 (1:5 ratio-freeze dried sample),  
HG1:1 (1:1 ratio-homogenised dried sample), HG1:3 (1:3 ratio- homogenised dried sample) 
or HG1:5 (1:5 ratio-homogenised dried sample)), was placed in a standard aluminium pan (40 
µL) with a vented lid. This was then crimped and heated from 50 to 180 °C at a scanning rate 
of 10 °C/min with nitrogen gas as the purge gas (DSC1 Mettler-Toledo, Switzerland). The 
enthalpy, onset temperatures and melting points of the starting materials and the various solid 
dispersions as well as their glass transition temperatures were analysed using the software 
provided by Mettler-Toledo, Switzerland.  
2.3.3. X-ray powder diffraction (XRPD) 
The XRPD patterns of each sample (INDO, SOL, SD1:1 (1:1 ratio-spray dried sample), 
SD1:3 (1:3 ratio-spray dried sample), SD1:5 (1:5 ratio-spray dried sample), FD1:1 (1:1 ratio-
freeze dried sample), FD1:3 (1:3 ratio-freeze dried sample), FD1:5 (1:5 ratio-freeze dried 
sample), HG1:1 (1:1 ratio-homogenised dried sample), HG1:3 (1:3 ratio- homogenised dried 
sample) and HG1:5 (1:5 ratio-homogenised dried sample)), were scanned in Bragg–Brentano 
geometry, over a scattering (Bragg, 2θ) angle range from 5 to 100°, in 0.02° steps at 
  
9 
 
1.5° min
−1
 using a D2 Phaser diffractometer (Bruker AXS GmbH, Karlsruhe, Germany) 
(Laity et al., 2015). Microsoft Excel was used to analyse the collected XRPD patterns. 
2.4. Assay measurements 
20 mg of each sample SD1:1 (1:1 ratio-spray dried sample), SD1:3 (1:3 ratio-spray dried 
sample), SD1:5 (1:5 ratio-spray dried sample), FD1:1 (1:1 ratio-freeze dried sample), FD1:3 
(1:3 ratio-freeze dried sample), FD1:5 (1:5 ratio-freeze dried sample),  HG1:1 (1:1 ratio-
homogenised dried sample), HG1:3 (1:3 ratio- homogenised dried sample) and HG1:5 (1:5 
ratio-homogenised dried sample)), was placed into a 100 mL volumetric flask and made up to 
volume using the pH 7.2 to allow it to dissolve. 1 mL of this dissolved solution was 
withdrawn using a micropipette and placed into a 10 mL volumetric flask, and made up to 
volume using the pH 7.2 media. This was carried out in triplicate for each sample. The INDO 
content in each sample was determined at a wavelength of 320 nm using a Cary 60 UV-Vis 
spectrophotometer (Agilent Technologies). The concentration of INDO in the various 
formulations were then calculated after subjecting the absorbance values through an equation 
of best fit derived from a calibration curve of INDO with an r
2
 value of 0.9993.   
 
2.5. Surface analysis of compacts and UV imaging of intrinsic dissolution rate (IDR) and 
pseudo IDR 
Compacts (3 mm) for surface analysis or UV imaging for IDR were produced by using 10 mg 
of either INDO, SD1:1 (1:1 ratio-spray dried sample), SD1:3 (1:3 ratio-spray dried sample), 
SD1:5 (1:5 ratio-spray dried sample), FD1:1 (1:1 ratio-freeze dried sample), FD1:3 (1:3 ratio-
freeze dried sample), FD1:5 (1:5 ratio-freeze dried sample),  HG1:1 (1:1 ratio-homogenised 
dried sample), HG1:3 (1:3 ratio-homogenised dried sample) or HG1:5 (1:5 ratio-
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homogenised dried sample) at a compression force of 100 kg for 1 min using a hand-crank 
press (Pion Inc). The focus variation microscope Alicona™ microscope (Alicona Imaging 
GmbH, Graz, Austria) was used for the surface assessment as previously reported by Ward et 
al., 2017 [41]. The surface assessment of the compacts prior to IDR (INDO drug) or pseudo 
IDR (for all the formulations made –the same set-up for determining IDR from the 
parent drug INDO was used in determining the images and values for the solid 
dispersion samples. This is what the authors are terming “pseudo IDR”) determination 
allowed the effect of the preparation method (spray drying, freeze drying and homogenising) 
of the solid dispersions on the developed interfacial (surface) area ratio (Sdr) to be 
determined over that of the parent drug INDO. The true surface area of the textured sample 
compared to that of a uniform flat surface of equal size is known as the Sdr. It is expressed as 
a percentage by which the true measured surface area exceeds that of the nominal uniform 
measurement area (Equation 1) allowing for a surface gain to be calculated. The texture 
aspect ratio parameter (Str) was used to assess the uniformity of the texture of the 
compacts for IDR or pseudo IDR determination. The area used in determining the Sdr 
and Str is depicted in Figure 1. The closer to 1 the Str value lies, the more uniform the 
surface is, whereas the closer to 0 the value is, the more likely a dominant texture 
direction is influencing the surface. This is in line with guidance described in ISO 25178 
[47]. The Surfstand™ software (Taylor Hobson, UK, and University of Huddersfield, UK) 
was used to analyse the acquired focus variation images to produce the 3D roughness 
maps in order to generate the values for both Sdr and Str.  
     
                                             
                    
                                     Equation 1 
The SDI2 flow through cell (Pion Inc) was then used in the determination of IDR or pseudo 
IDR (Figure 2a). The same compacts that were made and assessed for their surface texture 
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was used for IDR determination. This allowed the authors to determine if the surfaces 
impacted IDR or pseudo IDR measurements. Figure 2a displays the flow through set-up 
for IDR or pseudo IDR determination with a key explaining the various components 
involved. Figure 2b shows an example of the images that are produced from such 
analysis indicating the direction of flow, compact location, drug dissolution and where 
the drug measurement zone is. The molar extinction coefficient of INDO was 
experimentally determined by using a concentrations range of 2.8 x 10
-6
 to 1.4 x 10
-4
 
mol/L. The range of concentrations used was within the linear region and produced an 
r
2
 value of 0.999. All experiment were conducted in triplicates. pH 7.2 was used as the 
dissolution medium at a flow rate of 2 mL/min for 30 min at 37 °C. All experiments were 
conducted in triplicate and at a wavelength of 320 nm. 
 
2.6. UV imaging and dissolution of whole dosage form 
The schematic of how the whole dosage form cell (which is the additional capability of the 
new SDI2) operates is depicted in Figure 3a. Figure 3b shows an example of the images 
that are generated from whole dose analysis indicating the direction of flow, wire 
holder, whole dosage form, drug dissolution and where the drug measurement zone is. 
Capsules containing 2.5 mg of INDO or 2.5 mg INDO content determined from the assay 
measurements in section 2.4 from SD1:1 (1:1 ratio-spray dried sample), SD1:3 (1:3 ratio-
spray dried sample), SD1:5 (1:5 ratio-spray dried sample), FD1:1 (1:1 ratio-freeze dried 
sample), FD1:3 (1:3 ratio-freeze dried sample), FD1:5 (1:5 ratio-freeze dried sample),  
HG1:1 (1:1 ratio-homogenised dried sample), HG1:3 (1:3 ratio- homogenised dried sample) 
or HG1:5 (1:5 ratio-homogenised dried sample) were prepared using a size 0 hard gelatine 
capsules. These samples were then mounted using a wire holder and placed within the sample 
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holder. The whole dosage cell with glass beads added was inserted and connected to the fluid 
lines. The experiment was conducted using pH 7.2 at a flow rate of 8.2 mL/min at 37 °C. The 
release of INDO and the various solid dispersions prepared from the different techniques was 
imaged over 60 min at various time points at a wavelength of 320 nm. All experiments were 
conducted in triplicate. 
3. RESULTS AND DISCUSSION 
3.1. Solid-state analysis 
XRPD was used to confirm the nature of the prepared solid dispersion samples as well as the 
nature and starting polymorph of INDO. This analysis was conducted straight after sample 
preparation. The obtained XRPD patterns are depicted in Figure 4Error! Reference source 
not found.. Characteristic peaks of the samples were confirmed by the differences in the 
diffraction pattern between 5° and 40° 2θ. Characteristic peaks at 11.6, 16.8, 19.6, and 26.6° 
2θ suggest INDO was the γ-polymorph [17,48]. It was also evident from the diffractions that 
SOL was fully amorphous with no distinct crystalline peaks. The XRPD pattern in Figure 4a-
c indicated that regardless of the preparation method (spray drying, freeze drying and 
homogenisation) of solid dispersions, the resultant products were all in the amorphous state. 
The diffused halo diffraction pattern present therefore suggests that the crystalline INDO was 
molecularly dispersed within the SOL. This may potentially have implications on the pseudo 
IDR and dissolution rate of INDO in the solid dispersions. The XRD patterns of all the 
produced solid dispersions were assessed after a year of storage and were all found to be 
still amorphous (Supplementary material S1). 
The DSC thermograms of INDO, SOL, and the produced solid dispersions from the three 
different preparation methods are depicted in Figure 5. The sharp endothermic peak exhibited 
by INDO on the DSC at 161.98 °C corresponds to its melting point and confirmed the γ 
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polymorphic nature of INDO [28,49]. Figure 5 shows SOL is amorphous with a glass 
transition around 70 °C [50]. It was interesting to note also that the peak corresponding to 
INDO’s melting point at 161.98 °C was absent in all the solid dispersions (SD, FD and HG 
samples), further reinstating its amorphous state and confirming that INDO was molecularly 
dispersed in SOL. The glass transition temperature in the 1:1 SD (58.82 °C), 1:3 SD (60.26 
°C), 1:5 SD (63.61 °C), 1:1 FD (60.82 °C), 1:3 FD (58.98 °C), 1:5 FD (50.61 °C),  1:1 HG 
(48.13 and 66.33 °C), 1:3 HG (67.15 °C) and 1:5 FD (68.60 °C) samples was further proof of 
their amorphous state.  This therefore showed that the addition of SOL to INDO using the 
various preparation techniques inhibited the crystallisation of INDO. XRPD and DSC thus 
proved complimentary in determining the state of INDO in the solid dispersions. 
SEM images of INDO, SOL and the various solid dispersion samples are depicted in Figure 
6. The SEM images showed marked differences in the morphology and microstructure 
between the samples produced by SD, FD and HG techniques. All particles prepared by the 
three preparation methods had variable shapes and sizes. The SD process yielded spherical 
particles. The size of the obtained particles remained fairly consistent and uniform with the 
particles clustering together (Figure 6a). It was interesting to note that despite the FD and HG 
samples being subjected to the freeze drying process, they had different morphologies. The 
FD dispersions appeared to be highly porous with wrinkled surfaces and a relatively complex 
structure (Figure 6b). The HG samples however appeared to have no real structure to them 
with varied particle sizes (Figure 6c). This could be attributed to the homogenising process 
and could potentially have an effect on pseudo IDR and dissolution. 
 
3.2. Intrinsic dissolution rate 
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Ward et al., 2017 [41] used a focus variation microscope to show uneven and loose 
particulates on the surfaces of compacts ready for IDR UV imaging can give rise to erroneous 
data. This had been observed previously by Niederquell and Kuentz 2014 [32] using SEM. 
As the surface integrity of compact has been proven to be important [16], the surfaces of all 
compacts were extensively studied at 10 x magnifications on the focus variation instrument 
(as in schematic for figure 1). The 2D images in Figure 7 at the 10 x magnification show 
that all the samples (SD, FD and HG and the pure drug INDO) picked up the “rings” on the 
tooling surface. It was interesting to note also that the morphology of the SEM image of SOL 
(Figure 6a) was picked up on the compact surface (Figure 7).  Figure 7 shows a nice uniform 
surface produced from the spherical particles produced from the spray drying process. The 
complimentary Surfstand™ 3D images of the compacts in Figure 8 confirm changes in the 
surface parameters from INDO to the various formulations. Surfstand analysis of the INDO 
compact showed it had an Sdr (represented as a percentage) gain of 1.72 % at the 10x 
magnification. The Sdr value indicates the surface area gained as a result of the texture of the 
samples. It was interesting to observe how a change in the morphology affected the Sdr. The 
spray dried dispersions had the lowest surface gain (even lower than the INDO drug) for all 
the samples with the homogenised samples having the highest gains (Table 1) which may be 
due to the way the particles pack and compact due to their morphologies. Compression lines 
from the tooling can also be seen in these images (as indicated by the red arrows) as well as 
powder particulates (indicated by the black dashed circles) which may have implications on 
IDR determination. Hulse et al., 2012 [36] therefore reported using IDR values after the 3 
min mark from a UV imaging technique due to potential erroneous measurements as a result 
of drug particles on the surface. IDR results here (Table 1) are reported from the 5 min time 
point as reported in Asare-Addo et al., 2018 [16]. Another interesting observation was that 
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there was a uniformity of texture (Str) for all the samples with the exception of the 1:1 
homogenised samples which coincidently had the highest Sdr also (Table 1).    
The UV images from IDR determination of INDO and pseudo IDR determination from 
the solid dispersion samples are shown in Figure 9. Figure 9 showed some interesting 
phenomenon occurring for some of the solid dispersions which we believe we are reporting 
for the first time. The red dashed lines show “web like” strands produced during the pseudo 
IDR run. These seem to be generally prominent with increased SOL content in the solid 
dispersions. This is also visualised in the flow through cell taken out after the pseudo IDR 
run in the images depicted in Figure 10. The authors believe this to be a viscosity 
phenomenon due to the increased polymer levels. To rule out possible interactions or 
complexations, the authors have exploited isothermal calorimetry and additional pseudo IDR 
runs with the pure SOL, spray dried SOL, freeze dried SOL and various combinations with 
pure INDO (Supplementary material S2, S3 and S4). The IDR figures and values are depicted 
in Figure 11 and Table 1. These IDR and pseudo IDR values were obtained from the use 
of the molar extinction coefficient value (9590.5 M
-1
cm
-1
) obtained from the INDO 
concentration ranges explored from section 2.5. The black arrows in Figure 11 indicate 
increases/decreases in pseudo IDR at those time points possibly due to the behaviour of the 
compacts described (Figure 9). This visual way of determining IDR thus highlights the 
importance of this UV imaging technique in generating IDR or pseudo IDR values as it 
gives a visual into drug behaviour thereby allowing a formulator to give consideration to 
data gathered in the decision process. All the spray dried solid dispersions showed a 
significant decrease in the pseudo IDR values compared to the IDR of INDO (Table 1). The 
1:1 FD and HG samples both had improvement in their pseudo IDR values over the parent 
drug INDOs IDR. Both the 1:3 and 1:5 samples for the FD and HG samples however had 
lower pseudo IDR values than the IDR of INDO (Table 1) suggesting freeze drying and 
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homogenising at the 1:1 INDO:SOL ratio to be best candidates in improving the IDR of 
INDO. These mixed results maybe a combination of several factors that includes 
microstructure, viscosity at the surface of the compacts and solid fraction effects on samples. 
The INDO compacts were analysed using XRPD post IDR run was found to in the γ-
polymorph form (Supplementary material S5)  [17,48]. 
 
3.3. Whole dosage form imaging 
Assaying all the formulations produced allowed accurate determinations of drug content in 
the various ratios of the solid dispersions. Figure 12 shows the release as determined from the 
UV imaging of the INDO, SD, FD and HG solid dispersions. INDO had an average 
concentration of 1.62 ± 0.001 µg/mL over the 60 min period. The 1:1 SD, 1:3 SD and 1:5 SD 
had average concentrations of 5.42 ± 1.12 µg/mL, 6.62 ± 2.3 µg/mL and 3.53 ± 1.45 µg/mL 
respectively. The 1:1 FD, 1:3 FD and 1:5 FD had average concentrations of 4.78 ± 1.82 
µg/mL, 5.04 ± 0.94 µg/mL and 4.73 ± 2.08 µg/mL respectively. The 1:1 HG, 1:3 HG and 1:5 
HG had average concentrations of 6.07 ± 2.45 µg/mL, 5.00 ± 1.08 µg/mL and 3.79 ± 1.01 
µg/mL respectively. All the solid dispersions showed improvements in the average 
concentrations of INDO content over the parent or untreated INDO. This did not correlate in 
any way with the pseudo IDR data which showed two samples only to increase the 
dissolution rate over that of the parent drug INDO thereby highlighting the importance of 
using both imaging techniques. The authors suggest the behaviour of the compacts 
(contribution of SOL) as imaged in figure 9 to be responsible for the low pseudo IDR values 
experienced in the amorphous solid dispersions. The “lower” average concentration values 
for all the 1:5 INDO to SOL ratio samples was attributed to the gel like-layer (Figure 13) that 
had formed around the sample due to the higher SOL content after capsule shell dissolution. 
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This gel layer may have increased the diffusion pathway for INDO dissolution [51,52]. The 
area under the curve suggests the best five samples dissolution wise to be 1:3 SD > 1:1 HG > 
1:1 SD > 1:3 FD > 1:3 HG. This means that a ratio of INDO to SOL in these dispersions of 
up to 1:3 is sufficient to produce significant dissolution increases. The authors have also for 
the first time according to our knowledge used this UV imaging technique to capture the 
dissolution of a capsule with its tip coming off over time to allow drug into the media (Figure 
14). The full dosage imaging is also presented in Figure 15. These images allow a quick 
visualisation of the processes that yielded Figure 12. The 1:1 SD, 1:1 HG and 1:3 HG for 
example shows the quick saturation of the INDO in the image and this is represented in 
Figure 12 b and c. Again the poor solubility of INDO can be seen in the images as there was 
hardly any drug dissolved.  
 
4. Conclusion 
Successful solid dispersion formulations of INDO and SOL were made at three ratios (1:1, 
1:3 and 1:5 (drug:SOL)) using three manufacturing techniques. These were spray drying, 
freeze drying and homogenising. These solid dispersions were fully characterised and 
confirmed as being amorphous using DSC and XRPD. Pseudo IDR determined using a UV 
imaging technique set-up for IDR determinations deduced only two samples to have 
superior pseudo IDR values to the IDR of the parent drug INDO. The IDR and pseudo IDR 
UV images showed a phenomenon the authors are reporting for the first time where increased 
polymer content produced “web-like” strands that migrated to the top of the quartz cell which 
may have caused the decrease in the pseudo IDR values for the solid dispersions. The whole 
dose imaging (capsule) showed all the samples (spray drying, freeze drying and 
homogenising) had superior dissolution to that of the parent drug INDO. The area under the 
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curve suggested the best five samples dissolution wise to be 1:3 SD > 1:1 HG > 1:1 SD > 1:3 
FD > 1:3 HG meaning a ratio of INDO to SOL in these dispersion of up to 1:3 was sufficient 
to produce significant dissolution increases. As such a formulators choice of 
instrumentation/techniques to use may well come down to cost or instrument availability. 
This work highlighted the importance of having both complimentary IDR and whole dosage 
imaging techniques in giving a better understanding of solid dispersion systems.  
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Figure S1. XRPD analysis for the (a) INDO drug, SOL and the 1:1 SD, 1:3 SD and 1:5 SD 
dispersions, (b) INDO drug, SOL and the 1:1 FD, 1:3 FD and 1:5 FD dispersions, (c) INDO 
drug, SOL and the 1:1 HG, 1:3 HG and 1:5 HG dispersions all after 1 year storage. 
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Isothermal Titration Calorimetry 
Sample preparation 
A 0.020 % w/v soluplus dispersion was prepared using a 100 mL pH 6.8 phosphate buffer 
solution. The dispersion was stirred at 400 rpm for 24 h using a magnetic stirrer to ensure the 
polymer was fully hydrated. Indomethacin solution 0.010 % w/v was also prepared as above.  
Isothermal titration calorimetry  
Calorimetric binding studies were carried out at 25 °C on a Microcal VP ITC micro 
calorimeter used in high-gain equilibration mode. The reference power applied was 10 μcal s-
1
 and the sample cell contents were stirred at 307 rpm. Titration was carried out using the 
soluplus dispersion in the sample cell and the indomethacin solution in the syringe. This 
solution was added in 10 injections of 10 μl each into the sample cell every 500 s. The 
binding isotherm was analysed using Origin 7.0 (Microcal, Inc).  
Results 
ITC is a highly sensitive technique used to understand the thermodynamic characteristics of 
binding reactions (Duff, Jr., Grubbs, & Howell, 2011). This technique allows the observation 
of the real time binding events. Figure S2 depicts the isotherm between soluplus and 
indomethacin. Small dilution heats were observed suggesting that no interaction occurred 
between soluplus and indomethacin.   
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Figure S2. Real time isotherm betwwen indomethacin and soluplus showing no interaction 
between to two 
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Figures for IDR interaction studies 
 
Figure S3. Surface dissolution imaging  of bulk, freeze dried and spray dried soluplus 
exhibiting some swelling but no web-like behaviour 
 
Figure S4. Surface dissolution imaging  of bulk, freeze dried and spray dried soluplus with 
indomethacin in physical mixtures exhibiting some swelling but no web-like behaviour 
Note: The experiments for Figure S3 and S4 were obtained using pH 7.2 as the dissolution 
medium at a flow rate of 2 mL/min for 30 min at 37 °C. All experiments were conducted 
in triplicate and at a wavelength of 320 nm. 
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Figures for XRPD post IDR studies for INDO 
 
 
Figure S5. XRPD pattern for INDO pre and post UV surface dissolution imaging 
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Figures 
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Figure 5.  
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Figure 6. 
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Figure 8 
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Figure 9 
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Figure 10 
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Figure 11 
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Figure 12 
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Figure Captions 
Figure 1. (a) Schematic representation of the measurement zone for the 10x 
magnification used (b) 10x magnification field from which the developed interfacial 
(surface) area ratio (Sdr) and texture aspect ratio (Str) was determined.  
Figure 2. (a) A schematic representation of the flow through set-up for the SDI2 UV 
imaging system (b) A typical image produced from an intrinsic dissolution rate 
experiment with the various aspects of analysis. 
Figure 3. (a) A schematic representation of the whole dose set-up for the SDI2 UV 
imaging system (b) A typical image produced from a whole dosage assessment with the 
various aspects of analysis. 
Figure 4. XRPD analysis for the (a) INDO drug, SOL and the 1:1 SD, 1:3 SD and 1:5 SD 
dispersions, (b) INDO drug, SOL and the 1:1 FD, 1:3 FD and 1:5 FD dispersions, (c) INDO 
drug, SOL and the 1:1 HG, 1:3 HG and 1:5 HG dispersions. 
Figure 5. DSC traces for the (a) INDO drug, SOL and the 1:1 SD, 1:3 SD and 1:5 SD 
dispersions, (b) INDO drug, SOL and the 1:1 FD, 1:3 FD and 1:5 FD dispersions, (c) INDO 
drug, SOL and the 1:1 HG, 1:3 HG and 1:5 HG dispersions 
Figure 6. SEM images for the (a) INDO drug, SOL and the 1:1 SD, 1:3 SD and 1:5 SD 
dispersions, (b) 1:1 FD, 1:3 FD and 1:5 FD dispersions, (c) 1:1 HG, 1:3 HG and 1:5 HG 
dispersions 
Figure 7. Focus variation instrument images at 10x magnification of the representative 
compacts of INDO, SOL and respective solid dispersions. Images highlight impressions 
from the tooling that could potentially affect IDR measurements. Note: scale bar is 100 µm. 
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Figure 8. 3D images of the surface roughness data set gathered from the focus variation 
instrument of INDO, SOL and the respective solid dispersions. Images shown from 10x 
magnification to highlight particulates (dashed black circular lines) and impressions from the 
tooling that could potentially affect IDR measurements. 
Figure 9. Surface dissolution imaging of INDO and the 1:1 SD, 1:3 SD, 1:5 SD, 1:1 FD, 1:3 
FD, 1:5 FD, 1:1 HG, 1:3 HG and 1:5 HG dispersions at the 5, 10, 15 and 30 min time points. 
A red circle depicts the “web-like” development that may have resulted in 
decreases/increases in IDR values for some of the solid dispersions. Note: scale bar is 2 mm. 
Figure 10. Images captured of the web-like phenomenon within the IDR flow through 
cell taking place in the UV experiments. 
Figure 11. IDR or “pseudo” IDR as a function of time for the (a) INDO and spray dried 
formulations only. The purple inserts elaborates the relatively higher IDR or “pseudo” 
IDR values at the earlier time points which may be due to drug or solid dispersion dust 
particulates being on the surfaces of the compacts. (b) IDR for INDO (c) 1:1 SD, 1:1 FD 
and 1:1 HG (d) 1:3 SD, 1:3 FD and 1:3 HG (e) 1:5 SD, 1:5 FD and 1:5 HG dispersions. 
The black arrows indicate increases/decreases in IDR or “pseudo” IDR at those time 
points possibly due to the behaviour of the dispersions as in Figure 9 and 10. Note: IDR 
data was reported after the 5 min mark only for figures 11 b-e. Note: where standard 
deviations are not seen is because they are smaller than the marker. 
Figure 12. Amount of a) INDO (b) 1:1 SD, 1:1 FD and 1:1 HG dispersions, (c) 1:3 SD, 1:3 
FD and 1:3 HG dispersions, (d) 1:5 SD, 1:5 FD and 1:5 HG dispersions released over 60 
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min using the whole dosage cell. Note: where standard deviations are not seen is because 
they are smaller than the marker. 
Figure 13. Gel layer on remaining capsule after 60 min UV dissolution imaging. This was 
characteristic for the 1:5 SD, FD and HG samples. 
Figure 14. Full dosage imaging of a capsule. Red arrows indicate how the tip of the capsule 
comes off with time to allow the drug to go in solution. Note: scale bar is 4 mm. 
Figure 15. Full dosage imaging of a) INDO and the 1:1 SD, 1:3 SD, 1:5 SD, 1:1 FD, 1:3 FD, 
1:5 FD, 1:1 HG, 1:3 HG and 1:5 HG dispersions at the 1, 5, 10, 15, 30, 45 and 60 min. Note: 
Samples were imaged over a 60 min period. Note: scale bar is 4 mm. 
 
 
 
 
 
 
Tables 
Table 1. Intrinsic dissolution rates (IDR and pseudo IDR), developed interfacial 
(surface) area ratio (Sdr) and texture aspect ratio (Str) for INDO and the solid 
dispersions produced from the different preparation methods 
Formulation  IDR (µg/min/cm2)* Sdr **(%) Str** 
INDO 59.15 ± 0.23 1.72 0.776 
1:1 SD 24.22 ± 0.36 0.79 0.846 
1:3 SD 30.84 ± 0.33 0.86 0.797 
1:5 SD 19.21 ± 0.83 0.72 0.918 
1:1 FD 73.56 ± 1.65 16.29 0.892 
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1:3 FD 37.17 ± 0.83 5.75 0.675 
1:5 FD 16.72 ± 0.51 3.37 0.882 
1:1 HG 70.02 ± 9.77 44.65 0.362 
1:3 HG 31.32 ± 3.96 5.84 0.883 
1:5 HG 32.71 ± 13.86 9.14 0.804 
 
Note: * depicts n=3 experiments and **depicts n=10 experiments 
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Highlights 
1. Three preparation methods for making solid dispersion investigated 
2. UV imaging of IDR showed web-like strand migrating to the top of quartz cell potentially 
responsible for low IDR values 
3. Capsule tip coming off for drug dissolution to occur UV imaged for the first time 
4. Solid dispersions in ratio 1:1 and 1:3 sufficient to show significant dissolution profiles 
from UV imaging 
 
 
